drugset / Trial / NCT01518998
A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension
Phase 2
Completed
420 enrolled
Boryung Pharmaceutical Co., Ltd
Asan Medical Center · collabBusan National University Yangsan Hospital · collabCatholic University of Korea Saint Paul's Hospital · collabCheil General Hospital and Women's Healthcare Center · collabChonnam National University Hospital · collabChungnam National University · collabDaegu Catholic University Medical Center · collabDongGuk University · collabGachon University Gil Medical Center · collabHallym University Kangnam Sacred Heart Hospital · collabHanyang University Seoul Hospital · collabInha University Hospital · collabInje University · collabJeju National University Hospital · collabKangbuk Samsung Hospital · collabKorea University Guro Hospital · collabKyungpook National University Hospital · collabSamsung Medical Center · collabSeoul National University Bundang Hospital · collabSeoul National University Hospital · collabSoon Chun Hyang University · collabThe Catholic University of Korea · collabWonju Severance Christian Hospital · collabWonkwang University Hospital · collabYeungnam University Hospital · collab
RandomizedFactorialDouble-blindTreatment
Summary
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan
Timeline
- Start
- 2011-08
- Primary completion
- 2013-10
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amlodipine | Other / unclassified | 5 mg | — |
| Subject | Amlodipine | Other / unclassified | 10 mg | — |
| Subject | Fimasartan | Small molecule | 30 mg | — |
| Subject | Fimasartan | Small molecule | 60 mg | — |